Bvf Raised Its Position in Regulus Therapeutics (RGLS) by $9.67 Million as Share Price Rose; Weatherford Intl Plc (WFT) Shareholder Hotchkis & Wiley Capital Management Cut Its Position as Market Value Declined

January 14, 2018 - By Darrin Black

Hotchkis & Wiley Capital Management Llc decreased its stake in Weatherford Intl Plc (WFT) by 1.89% based on its latest 2017Q3 regulatory filing with the SEC. Hotchkis & Wiley Capital Management Llc sold 206,900 shares as the company’s stock declined 8.25% while stock markets rallied. The institutional investor held 10.73 million shares of the metal fabrications company at the end of 2017Q3, valued at $49.15 million, down from 10.94 million at the end of the previous reported quarter. Hotchkis & Wiley Capital Management Llc who had been investing in Weatherford Intl Plc for a number of months, seems to be less bullish one the $4.22B market cap company. The stock increased 1.92% or $0.08 during the last trading session, reaching $4.25. About 22.50 million shares traded. Weatherford International plc (NYSE:WFT) has risen 2.15% since January 14, 2017 and is uptrending. It has underperformed by 14.55% the S&P500.

Bvf Inc increased its stake in Regulus Therapeutics Inc (RGLS) by 294.93% based on its latest 2017Q3 regulatory filing with the SEC. Bvf Inc bought 9.67 million shares as the company’s stock rose 26.09% with the market. The hedge fund held 12.95 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $16.19 million, up from 3.28 million at the end of the previous reported quarter. Bvf Inc who had been investing in Regulus Therapeutics Inc for a number of months, seems to be bullish on the $127.87M market cap company. The stock increased 1.65% or $0.02 during the last trading session, reaching $1.23. About 586,224 shares traded. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 73.20% since January 14, 2017 and is downtrending. It has underperformed by 89.90% the S&P500.

Among 7 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Regulus Therapeutics had 27 analyst reports since August 5, 2015 according to SRatingsIntel. The company was downgraded on Monday, January 30 by Needham. The rating was maintained by BMO Capital Markets with “Hold” on Monday, June 12. The firm has “Hold” rating by Needham given on Wednesday, August 2. Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating on Wednesday, March 29. Wedbush has “Outperform” rating and $6 target. The stock has “Neutral” rating by Chardan Capital Markets on Wednesday, August 2. Chardan Capital Markets maintained it with “Buy” rating and $500 target in Tuesday, June 13 report. As per Wednesday, August 2, the company rating was maintained by BMO Capital Markets. The firm has “Hold” rating given on Tuesday, October 3 by Needham. BMO Capital Markets downgraded the stock to “Market Perform” rating in Tuesday, June 28 report. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given on Wednesday, December 20 by Wedbush.

Bvf Inc, which manages about $999.89M and $786.73M US Long portfolio, decreased its stake in Anaptysbio Inc by 280,066 shares to 1.38 million shares, valued at $48.20 million in 2017Q3, according to the filing. It also reduced its holding in Cytokinetics Inc (NASDAQ:CYTK) by 749,300 shares in the quarter, leaving it with 1.24 million shares, and cut its stake in Pieris Pharmaceuticals Inc.

Investors sentiment increased to 1.35 in 2017 Q3. Its up 0.74, from 0.61 in 2017Q2. It is positive, as 9 investors sold RGLS shares while 11 reduced holdings. 11 funds opened positions while 16 raised stakes. 58.85 million shares or 159.76% more from 22.65 million shares in 2017Q2 were reported. State Street has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Broadfin Cap Limited Company owns 4.29 million shares or 0.79% of their US portfolio. Macquarie Gru Ltd owns 20,000 shares or 0% of their US portfolio. Mariner Wealth Advsr Limited Liability Co invested 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS). Meeder Asset Mgmt owns 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 4,359 shares. Millennium Mngmt Lc reported 0% stake. Moreover, Ecor1 Capital Limited Co has 0.87% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS). Victory Capital Mgmt invested in 277,240 shares. Morgan Stanley holds 5,699 shares. Element Capital Mngmt Ltd Liability Com owns 60,473 shares. Northern Tru holds 187,492 shares or 0% of its portfolio. 20,248 were reported by Hightower Advsr. Guggenheim Cap Ltd Company has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 29,097 shares. 492,191 are owned by Wells Fargo & Mn. Bourgeon Capital Mgmt Limited Company accumulated 0.03% or 40,804 shares.

Investors sentiment decreased to 0.95 in Q3 2017. Its down 0.16, from 1.11 in 2017Q2. It fall, as 41 investors sold WFT shares while 94 reduced holdings. 39 funds opened positions while 89 raised stakes. 1.10 billion shares or 1.67% more from 1.09 billion shares in 2017Q2 were reported. Baldwin Brothers Ma accumulated 10,000 shares. Poplar Forest Cap stated it has 6.57 million shares. Oppenheimer Asset Incorporated holds 0.23% or 1.93 million shares in its portfolio. Boothbay Fund Management Ltd Liability Corporation reported 54,998 shares stake. 8.20 million are held by Goldman Sachs Grp Inc Inc Inc. Stratos Wealth Prtn Limited stated it has 13,770 shares or 0% of all its holdings. Gamco Et Al invested in 10.00 million shares or 0.28% of the stock. Ameriprise Finance holds 103,179 shares. Tci Wealth Incorporated holds 0% or 169 shares in its portfolio. Gabelli And Co Invest Advisers stated it has 0.03% in Weatherford International plc (NYSE:WFT). 28,500 were accumulated by Daiwa Securities Grp Inc Inc. Hotchkis Wiley Mngmt Limited Com owns 10.73 million shares. Cubist Systematic Strategies Ltd Liability invested in 447,470 shares or 0.11% of the stock. Dc Advsr Limited invested in 1.51% or 500,000 shares. Nokota Management Ltd Partnership owns 5.30M shares or 0.59% of their US portfolio.

Analysts await Weatherford International plc (NYSE:WFT) to report earnings on February, 7. They expect $-0.20 earnings per share, up 37.50% or $0.12 from last year’s $-0.32 per share. After $-0.22 actual earnings per share reported by Weatherford International plc for the previous quarter, Wall Street now forecasts -9.09% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts